All Stories

  1. Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis

    Article • Future Oncology, September 2016, Future Medicine

    Omar Abdel-Rahman, Dr Hesham Elhalawani

  2. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis

    Article • Future Oncology, February 2016, Future Medicine

    Omar Abdel-Rahman, Dr Hesham Elhalawani

  3. Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis

    Article • Future Oncology, December 2015, Future Medicine

    Omar Abdel-Rahman, Dr Hesham Elhalawani

  4. Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers

    Article • Therapeutics and Clinical Risk Management, July 2015, Dove Medical Press

    Omar Abdel-Rahman, Dr Hesham Elhalawani